European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II

S Krege, J Beyer, R Souchon, P Albers, W Albrecht, F Alyaba, M Bamberg, I Bodrogi, C Bokemeyer, E Cavallin-Stahl, J Classen, C Clemm, G Cohn-Cedermark, S Culine, G Daugaard, PHM de Mulder, M De Santis, M de Wit, Ronald de Wit, HG DerigsKP Dieckmann, A Dieing, JP Droz, M Fenner, K Fizazi, A Flechon, SD Fossa, XG del Muro, T Gauler, L Geczi, A Gerl, JR Germa-Lluch, S Gillessen, JT Hartmann, M Hartmann, A Heidenreich, W Hoeltl, A Horwich, R Huddart, M Jewett, J Joffe, WG Jones, L Kisbenedek, O Klepp, S Kliesch, KU Koehrmann, C Kollmannsberger, M Kuczyk, P Laguna, OL Galvis, V Loy, MD Mason, GM Mead, R Mueller, C Nichols, N Nicolai, T Oliver, D Ondrus, GON Oosterhof, L Paz-Ares, G Pizzocaro, J Pont, T Pottek, T Powles, O Rick, G Rosti, R Saluioni, J Scheiderbauer, HU Schmelz, H Schmidberger, HJ Schmoll, M Schrader, F Sedlmayer, NE Skakkebaek, A Sohaib, S Tjulandin, P Warde, S Weinknecht, L Weissbach, C Wittekind, E Winter, L Wood, H von der Maase

Research output: Contribution to journalArticleAcademicpeer-review

255 Citations (Scopus)


Objectives: The first consensus report that had been presented by the European Germ Cell Cancer Consensus Group (EGCCCG) in 2004 has found widespread approval by many colleagues throughout the world. In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, The Netherlands. Methods: Medical oncologists, urologic surgeons, radiation oncologists as well as pathologists from several European countries reviewed and discussed the data that had emerged since the 2002 conference and incorporated the new data into updated and revised guidelines. As for the first meeting the methodology of evidence-based medicine (EBM) was applied. The results of the discussion were compiled by the writing committee. All participants have agreed to this final update. Results: The second part of the consensus paper includes the treatment of metastasised disease, residual tumour resection, salvage therapy, follow-up, and late toxicities. Conclusions: Whereas the vast majority of the recommendations made in 2004 remain valid 3 yr later, refinements in the treatment of early-stage as well as of advanced-stage testicular cancer have emerged from clinical trials. Despite technical improvements, expert clinical skills will continue to be one of the major determinants for the prognosis of patients with germ cell cancer. in addition, the particular needs of testicular cancer survivors have been acknowledged. (C) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)497-513
Number of pages17
JournalEuropean Urology
Issue number3
Publication statusPublished - 2008

Research programs

  • EMC MM-03-86-08

Cite this